"id","versionIdentifier","rationale","instanceType","uuid:ID"
"StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","7927ff6a-5839-4484-b128-71586040bc74"
